What’s in, what’s out in R&D for U.S.-India stakeholders
BioCentury-USAIC survey of industry execs finds hot spots of enthusiasm, as they look beyond the pandemic and the downturn
The post-pandemic market downturn will end in 2023-24, say nearly 60% of respondents to the Annual BioPharma & Healthcare Summit survey, while 22% believe it will end this year.
Call it optimism or realism, but the vast majority of attendees at the virtual 2022 USA-India Chamber of Commerce summit say there’s an end in sight to the bear market within a year or two, an indication that industry professionals are in step with buysiders on the light at the end of the tunnel. ...